Nektar Therapeutics names new independent director
16 November 2021 -

Nektar Therapeutics (NASDAQ: NKTR), a US-based biopharmaceutical company, announced on Monday that it has named Diana M Brainard, MD as its independent director.

Dr Brainard brings more than two decades of experience working in the healthcare sector and academia to Nektar. Presently, she serves as chief executive officer of AlloVir Inc. She also held the position of a director on the AlloVir board of directors and is a member of the TriNetX Strategic Advisory Board. She has served as senior vice president and head of the Virology therapeutic area at Gilead Sciences Inc.

Howard W Robin, Nektar president and chief executive officer, 'We are very pleased to welcome Diana to our board of directors. Her wealth of experience in clinical development, regulatory strategy and successful commercial launches will be instrumental in Nektar's operations as we continue to advance our pipeline of immune-oncology and immunology candidates through upcoming milestones.'